We are very pleased to announce that Carolina Faune will be joining the sales and marketing team in Previwo as Director of Market Development. Based in Bergen, Norway, Carolina will be leading Previwo’s expansion to new markets as well as work to strengthen our cooperation with customers and key stakeholders in Norway and other existing markets.
Carolina is a veterinarian with an MBA from Universidad Austral de Chile and brings more than 20 years of experience working in the aquaculture industry. Before joining Previwo, Carolina held the position of Global Market Development Leader in Benchmark Animal Health.

Carolina has a very solid understanding and strategic perspective of the aquaculture industry world-wide, having previously held key global roles at Novartis and Elanco.

Carolina says ’I am thrilled for the opportunity to join Previwo and I am already impressed by Previwo´s team in Norway. As a veterinarian I am passionate about finding innovative ways to improve the health of our fish populations, a mission which is central to Previwo. We share the principles of bringing sustainable solutions and the long-term view through investing on our people and pipeline together with our customers and key stakeholders. 

I look forward to work closely with the industry globally and see how Previwo’s solutions can contribute to sustainable growth’

Previwo is a biotechnology company, based in Oslo, Norway, that researches, develops, and produces biologicals such as probiotics and vaccines for better fish health.  Previwo is committed promoting the use of sustainable biological solutions to improve fish welfare and farm productivity. Previwo’s first product; Stembiont™, is easy-to-use probiotic application, delivered through water, usually in the anaesthetic bath in conjunction with vaccination. Probiotics are usually considered for application via feed, and act primarily in the intestinal tract, but with our application, their beneficial effects extend throughout the body. This is evidenced by reduction in the risk of parasitic infection with salmon lice, bacterial ulcer disease, improved growth rates and survival in farmed salmon.

‘We are confident that Carolina, with her background and international roles, will add valuable competence to the scale-up of the Company in this key phase’ CEO, Kira Salonius tells. ‘With our innovative microbial solutions available in Norway and existing markets in Faroes and Iceland, together with market expansion plans in Chile, Canada, UK and EU, we are well positioned to contribute conferred health benefits to farmed fish globally’.